Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Scott who wrote (1418)	1/15/1998 11:42:00 AM
From: Roudy	Read Replies (1) \| Respond to of 1762

Scott, Thanks for the great explanation on label use. The recent run up in the stock would indicate a good response to Rituxan IMO. On a technical view, the point & figure chart gave a technical breakout buy signal yesterday. The traditional price volume bar chart looks good too. A move above forty would indicate a breakout on it as well. IMO, Don

To: Scott who wrote (1418)	1/15/1998 3:22:00 PM
From: Maurice Winn	Read Replies (2) \| Respond to of 1762

Thanks Scott, I gather from your explanation that a doctor could in fact use Rituxan on other CD20 antigen lymphoma patients, even though they are not relapsed or follicular. Correct? Even though there had not been clinical trials to demonstrate efficacy in that particular application. Sorry to repeat what you said, but I want to be certain of what you mean. Also, I understand there are several states already [USA states] and a trend for more to take the same approach, which leave use of drugs to the doctor patient relationship. If a patient and doctor decide to use a product, they don't have to have approval of FDA or the state involved. Correct? Your last sentence seems to me to be the key to the whole business. Because of the complexity of people's biology and the afflictions which assail them, every case is an experiment which requires expert attention to the details of the case. Blanket approvals or denials of products or treatments can never work on people. It doesn't work even on production of straightforward material goods like a telephone or toothpick as the centrally planned, state owned countries found after trying for decades. The centrally planned, state controlled, blanket approving medical systems aren't working either and bodies are strewn around as evidence. But dead people has never been much of a barrier to authoritative people. Thanks again for the explanation. Maurice